Objectives: We have investigated whether chemotherapy for HIV-related systemic non-Hodgkin's lymphoma (NHL) affects the pharmacokinetics of protease inhibitors. Patients and methods: This was a prospective, open-label, non-randomized, two-way crossover trial in HIV-1-infected patients treated with highly active antiretroviral therapy and chemotherapy for NHL. Seven patients received indinavir at a dosage of 800 mg three times daily and three patients received nelfinavir at a dosage of 750 mg three times daily. Chemotherapy consisted of adriamycin, cyclophosphamide, vincristine and prednisolone (CHOP). Each patient had blood samples for protease inhibitor pharmacokinetics drawn concomitantly with or independently of the CHOP cycle. Results: When indinavir was given concomitantly with CHOP, the AUC0-8 increased by 38% (20.5 ± 9.0 versus 14.9 ± 9.5 mg·h/L; P = 0.03), and was comparable to historical controls. By contrast, the AUC0-8 of indinavir administered without CHOP was lower than expected. A similar trend was observed with nelfinavir. Likewise, we observed a significant number of patients with C0 and C8 below the IC50 for the wild-type virus (0.1 mg/L) when the drug was administered without CHOP. Conclusions: Therapeutic drug monitoring of protease inhibitors should be part of the work-up in HIV-infected patients receiving chemotherapy for NHL.
- Therapeutic drug monitoring
ASJC Scopus subject areas